AFP and neoplasm: RETREAT stratifies 5-year recurrence risk from < 3% in patients without viable tumor or vascular invasion on explant and AFP ≤ 20 ng/mL (i.e. RETREAT score of 0) up to 75% in the highest risk patients (RETREAT ≥ 5).